GNI Group Ltd
TSE:2160
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GNI Group Ltd
Cash Taxes Paid
GNI Group Ltd
Cash Taxes Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Taxes Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
GNI Group Ltd
TSE:2160
|
Cash Taxes Paid
¥763m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
3
|
3-D Matrix Ltd
TSE:7777
|
Cash Taxes Paid
¥27m
|
CAGR 3-Years
133%
|
CAGR 5-Years
86%
|
CAGR 10-Years
36%
|
|
|
SanBio Co Ltd
TSE:4592
|
Cash Taxes Paid
¥1.1m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
PeptiDream Inc
TSE:4587
|
Cash Taxes Paid
¥8.1B
|
CAGR 3-Years
175%
|
CAGR 5-Years
277%
|
CAGR 10-Years
32%
|
|
|
Takara Bio Inc
TSE:4974
|
Cash Taxes Paid
¥654m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-6%
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Cash Taxes Paid
¥4m
|
CAGR 3-Years
40%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
GNI Group Ltd
Glance View
GNI Group Ltd. engages in the development, research, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 629 full-time employees. The company went IPO on 2007-08-31. The firm is engaged in the development of therapeutic agents for diseases that have many sufferers in Asian countries such as Japan and China, as well as clinical trial and bio-verification test businesses. The company is engaged in research and development of therapeutic agents, including F647 for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis) and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
See Also
What is GNI Group Ltd's Cash Taxes Paid?
Cash Taxes Paid
763m
JPY
Based on the financial report for Dec 31, 2025, GNI Group Ltd's Cash Taxes Paid amounts to 763m JPY.
What is GNI Group Ltd's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
9%
Over the last year, the Cash Taxes Paid growth was -65%. The average annual Cash Taxes Paid growth rates for GNI Group Ltd have been -12% over the past three years , 9% over the past five years .
